METHODS AND MATERIALS Facial skin aging assessments performed by four blinded dermatologists were correlated with plasma isoprostane levels
in 46 healthy, nonsmoking Japanese women aged 45 to 60. RESULTS Individuals whose assessed skin age exceeded chronological age had mean plasma isoprostane levels of PGF2a and 8-iso-PGF2a that were higher than those whose skin age was assessed to be less than chronological age ( p =.001 and.001, respectively). These results remained statistically significant when adjusted for confounding variables ( 8-iso-PGF2a, p =.02; PGF2a, p =.03).
CONCLUSIONS Plasma isoprostanes as markers of accelerated aging of the skin merit further study.”
“Despite www.selleckchem.com/products/lonafarnib-sch66336.html extensive research, the mortality associated with sepsis in hospitals remains very high. We have evaluated the protective immunomodulatory effect of thalidomide alone or with Augmentin in Klebsiella see more pneumoniae B5055-induced sepsis in BALB/c mice. The mouse model of sepsis was developed by placing K. pneumoniae B5055 entrapped in fibrin and thrombin clots in
the peritoneal cavity of mice. The septic mice were treated with thalidomide alone (30 mg/kg/day/po), Augmentin alone (20 mu g/ml/ip) and with their combination. The thalidomide-alone treated mice showed 75% survival whereas 60% of the Augmentin-alone treated group survived. Combination treatment provided 100% survival. Treatment with thalidomide alone significantly (p<0.05) decreased interleukin-1 alpha (IL-1 alpha), nitric oxide (NO) and malondialdehyde (MDA) levels in the serum without significantly (p<0.05) decreasing the bacterial count in blood. Augmentin alone
only decreased the bacterial load in blood significantly (p<0.05). However, a combination of thalidomide with Augmentin significantly (p<0.05) decreased both the bacterial count and inflammatory mediators.”
“OBJECTIVE: The delay between the availability of clinical evidence and
its application to the care of patients with acute coronary syndrome (ACS)
in the Kingdom of Saudi Arabia remains undefined. The Saudi Project for
Assessment of Coronary Events LDN-193189 mouse (SPACE) registry provides a comprehensive
view of the current diagnostic and treatment strategies for patients
with ACS; thus, the registry may be used to identify opportunities to
improve the care of these patients.
METHODS: Eight hospitals in different regions of Saudi Arabia were
involved in the pilot phase of the registry, from December 2005 to
July 2006. The study patients included individuals with ST segment elevation
myocardial infarction (STEMI), non-STEMI and unstable angina.
RESULTS: A total of 435 patients (77% men and 80% Saudis) with a mean
age of 57.1 years were enrolled.